Courtesy of Dr. Carlos Fava. TAVR has matured over time and has advanced onto low risk patients, but one of its greatest challenges continues to be bicuspid valve patients. These represent between 1% and 2% of the population and over 20% of young adults requiring surgical valve replacement (SAVR). The study looked at 27,086 patients<a href="https://solaci.org/en/2020/08/28/good-evolution-of-bicuspid-valves-with-evolute-or-evolute-pro/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Bicuspid aortic valves are found in approximately 2% of patients and represent the most frequent cause of aortic stenosis in young adults requiring valve replacement. Though TAVR has advanced significantly, this entity has not yet been included in the different randomized studies. At present, we have data from different reports,<a href="https://solaci.org/en/2020/08/21/sapien-3-good-outcomes-in-bicuspids/" title="Read more" >...</a>
Continuous electrocardiographic monitoring pre-transcatheter aortic valve replacement (TAVR) detected arrhythmic events in almost half the patients analyzed in this study (which will be published soon in JACC Interventions). A fourth of these patients needed urgent therapeutic actions before the procedure. Previous conduction disorders—particularly, right bundle branch block and chronic renal insufficiency—were linked to a higher<a href="https://solaci.org/en/2020/08/18/arrhythmias-wrongfully-linked-to-tavr/" title="Read more" >...</a>
The Latin American Society of Interventional Cardiology, through the SOLACI Research Department, is conducting a survey to determine the reasons why transcatheter aortic valve replacement (TAVR) was NOT conducted in patients with severe aortic stenosis in Latin America (from January to December 2019). Dr. Ricardo Allende, from San Luis Potosí (Mexico), and Dr. Pablo Lamelas,<a href="https://solaci.org/en/2020/08/07/solaci-research-survey-reasons-not-to-conduct-tavr-in-latin-america/" title="Read more" >...</a>
This study looked at patients with moderate to severe left ventricular hypertrophy and aortic stenosis treated with transcatheter aortic valve replacement (TAVR). Patients with reduced hypertrophy had lower mortality and fewer hospitalizations at 5 years. It included all moderate to severe risk patients with ventricular hypertrophy undergoing TAVR in the studies and registries PARTNER (I,<a href="https://solaci.org/en/2020/07/16/post-tavr-regression-of-ventricular-mass/" title="Read more" >...</a>
The “arms race”among transcatheter valves has been vertiginous. By the time we received the mid- or long-term outcomes of studies focused on a given valve, we were already using its next generation in clinical practice. As a result, there is little information addressing which valve is the best. Nowadays, this “arms race” has reached a<a href="https://solaci.org/en/2020/06/24/self-expanding-valve-vs-balloon-expandable-valve-randomized-head-to-head/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Transcatheter aortic valve replacement (TAVR) has shown benefit and is currently moving towards low-risk patients, as well as bicuspid aortic valves and (to a lower extent) aortic regurgitation. However, we must ponder on which valve should be used on each patient: balloon-expandable (BE) or self-expanding (SE) valve? They represent different technologies<a href="https://solaci.org/en/2020/06/03/tavr-balloon-expandable-or-self-expanding-valves-which-is-the-answer/" title="Read more" >...</a>
01- Management of Infarction During the COVID-19 Pandemic Patients with cardiovascular disease infected with COVID-19 are at a particular risk for morbidity and mortality. In any case, it should be noted that most patients requiring cardiovascular care due to ischemic heart disease, peripheral vascular disease, or structural heart disease are not infected. Read more HERE<a href="https://solaci.org/en/2020/06/03/the-most-read-scientific-articles-of-may-in-interventional-cardiology/" title="Read more" >...</a>
01- ECS Guidelines for COVID-19 Management One of the first statements in this document points out these are not “regular guidelines” developed after thorough analysis of all the available evidence published since the last update. Instead, they are meant to provide temporary basic management pointers on how to handle different scenarios of cardiac patients in the<a href="https://solaci.org/en/2020/05/06/the-most-read-scientific-articles-on-interventional-cardiology-in-april/" title="Read more" >...</a>
The assessment of all severe aortic stenosis patients at intermediate risk of the SURTAVI was finally completed, confirming inferiority against the traditional surgical replacement (SAVR) in hard points such as all-cause mortality and disabling stroke. The aim of this study was to report SURTAVI 2-year outcomes (Surgical Replacement and Transcatheter Aortic Valve Implantation) and confirm<a href="https://solaci.org/en/2020/04/29/surtavi-follow-up-completed-with-good-news/" title="Read more" >...</a>